Great Point Partners LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Great Point Partners LLC reported 29 stock positions worth $308.4 million. Its top holding was Apogee Therapeutics (APGE) at 9.2% of the portfolio, followed by Amylyx Pharmaceuticals (AMLX, 6.9%) and Zura Bio (ZURA, 6.5%). Compared with Q3 2025, it opened 12 new positions, sold out of 11, added to 6 and reduced 4. The biggest buy was a new position in Disc Medicine (IRON) and the biggest sale Rezolute (RZLT, shares −61%).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $308.4M (Q4 2025)
- SEC Filing
- 0001172661-26-001093 ↗ filed Feb 17, 2026
Holdings Value
Holdings 29 stocks · $308.4M
| APGE Apogee Therapeutics Inc. | 9.15% | 374,000 | $28.2M | Add +23.0% |
| AMLX Amylyx Pharmaceuticals Inc. | 6.85% | 1,750,000 | $21.1M | Add +2.9% |
| ZURA Zura Bio Ltd. | 6.48% | 3,815,930 | $20.0M | No change |
| IRON Disc Medicine Inc. | 6.44% | 250,000 | $19.9M | New |
| RAPT Rapt Therapeutics Inc. | 6.38% | 581,187 | $19.7M | New |
| IMVT Immunovant Inc. | 6.18% | 750,000 | $19.1M | Add +50.0% |
| SLNO Soleno Therapeutics Inc. | 6.00% | 400,000 | $18.5M | Add +77.8% |
| VOR Vor Biopharma Inc. | 5.81% | 1,370,107 | $17.9M | New |
| DNTH Dianthus Therapeutics Inc. | 4.68% | 350,000 | $14.4M | Add +31.7% |
| JBIO Jade Biosciences Inc. | 4.03% | 806,273 | $12.4M | Add +27.4% |
| KALV Kalvista Pharmaceuticals Inc. | 3.59% | 685,632 | $11.1M | New |
| CTNM Contineum Therapeutics Inc. Class A | 2.96% | 800,000 | $9.1M | New |
| EPRX Eupraxia Pharmaceuticals Inc. | 2.94% | 1,200,000 | $9.1M | No change |
| FULC Fulcrum Therapeutics Inc. | 2.93% | 800,000 | $9.0M | New |
| NKTR Nektar Therapeutics | 2.89% | 210,732 | $8.9M | Reduce -29.8% |
| UPB Upstream Bio Inc. | 2.64% | 300,000 | $8.1M | No change |
| NGNE Neurogene Inc. | 2.34% | 350,000 | $7.2M | Reduce -21.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 2.24% | 300,000 | $6.9M | New |
| CNTX Context Therapeutics Inc. | 2.23% | 4,683,711 | $6.9M | No change |
| CGEM Cullinan Therapeutics Inc. | 2.13% | 634,032 | $6.6M | New |
| EVMN Evommune Inc. | 1.80% | 325,000 | $5.6M | New |
| ORKA Oruka Therapeutics Inc. | 1.80% | 183,330 | $5.6M | No change |
| SLN Silence Therapeutics PLC-ADR | 1.59% | 808,032 | $4.9M | New |
| UNCY Unicycive Therapeutics Inc. | 1.49% | 796,558 | $4.6M | No change |
| CLYM Climb Bio Inc. | 1.27% | 979,534 | $3.9M | New |
| SANA Sana Biotechnology Inc. | 0.92% | 700,000 | $2.8M | No change |
| PHVS Pharvaris NV | 0.74% | 82,800 | $2.3M | Reduce -46.6% |
| AVTX Avalo Therapeutics Inc. | 0.73% | 124,666 | $2.3M | New |
| RZLT Rezolute Inc. | 0.73% | 951,809 | $2.2M | Reduce -61.2% |
Portfolio Sells Q3 2025 → Q4 2025
| RZLT Rezolute Inc. | Reduce -61.2% | 0.73% | −8.89 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −6.23 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −5.32 |
| NKTR Nektar Therapeutics | Reduce -29.8% | 2.89% | −4.24 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −3.44 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −3.35 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −2.19 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −2.06 |
| TSHA Taysha Gene Therapies Inc. | Sold out | 0.00% | −2.05 |
| DBVT DBV Technologies SA-Spon ADR | Sold out | 0.00% | −1.58 |
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −1.54 |
| ABSI Absci Corp. | Sold out | 0.00% | −1.01 |
| NGNE Neurogene Inc. | Reduce -21.7% | 2.34% | −0.90 |
| PHVS Pharvaris NV | Reduce -46.6% | 0.74% | −0.87 |
| PLRX Pliant Therapeutics Inc. | Sold out | 0.00% | −0.53 |
Portfolio Buys Q3 2025 → Q4 2025
| IRON Disc Medicine Inc. | New | 6.44% | +6.44 |
| RAPT Rapt Therapeutics Inc. | New | 6.38% | +6.38 |
| VOR Vor Biopharma Inc. | New | 5.81% | +5.81 |
| APGE Apogee Therapeutics Inc. | Add +23.0% | 9.15% | +4.11 |
| KALV Kalvista Pharmaceuticals Inc. | New | 3.59% | +3.59 |
| CTNM Contineum Therapeutics Inc. Class A | New | 2.96% | +2.96 |
| FULC Fulcrum Therapeutics Inc. | New | 2.93% | +2.93 |
| IMVT Immunovant Inc. | Add +50.0% | 6.18% | +2.82 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 2.24% | +2.24 |
| CGEM Cullinan Therapeutics Inc. | New | 2.13% | +2.13 |
| EVMN Evommune Inc. | New | 1.80% | +1.80 |
| JBIO Jade Biosciences Inc. | Add +27.4% | 4.03% | +1.75 |
| SLN Silence Therapeutics PLC-ADR | New | 1.59% | +1.59 |
| CLYM Climb Bio Inc. | New | 1.27% | +1.27 |
| AVTX Avalo Therapeutics Inc. | New | 0.73% | +0.73 |
| DNTH Dianthus Therapeutics Inc. | Add +31.7% | 4.68% | +0.31 |
| SLNO Soleno Therapeutics Inc. | Add +77.8% | 6.00% | −0.35 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +2.9% | 6.85% | −2.79 |
Options Activity Q3 2025 → Q4 2025
| HRMY Harmony Biosciences Holdings | call | Sold out | 85,000 | $2.3Mbefore exit |
| CAPR Capricor Therapeutics Inc. | put | Sold out | 87,700 | $632Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |